BioCap marks one of the key events in the calendar for any business involved with life sciences investment. It is a real pleasure to be involved in such an interesting and relevant panel discussion.
(PRWEB UK) 27 September 2017
Bernard Ross, CEO of Sky Medical Technology, the parent company of Firstkind, will be taking part in a panel discussion at the sixth annual BioCap Conference on Thursday 28 September at Alderly Park. BioCap is the specialist life science investment and showcase conference in the North of England, highlighting the wealth of investment opportunities within the sector.
Bernard is taking part in the ‘Venturing: What is Happening Nationally and Internationally’ session alongside Senior Executives from AstraZeneca, Syncona Investment Management, Silicon Valley Bank and Ernst & Young. The panel will be discussing key themes, before taking questions from the audience.
Commenting on his involvement, Bernard Ross said: “BioCap marks one of the key events in the calendar for any business involved with life sciences investment. It is a real pleasure to be involved in such an interesting and relevant panel discussion”.
“I look forward to bringing to the discussion our first-hand experience as the beneficiary of recent corporate venture capital investments from companies based in Japan, Canada and the USA”.
About Sky Medical Technology & Firstkind Ltd
Sky Medical Technology Ltd, parent company of Firstkind Ltd, is a UK based medical devices company that has developed a ground-breaking neuromuscular electrostimulation platform, OnPulse™. The company develops a range of products tailored to different medical applications, selling both direct, through partnerships or distributors in each clinical area. Clinical areas of interest include DVT prevention, reduction of oedema, wound healing, elite-sport recovery, and continence. The goal in each clinical area is to improve clinical outcomes and patient care whilst saving health system resources.